Liver cancer is treatable, and in some cases curable, depending on how early it’s caught and how well the liver itself is functioning. About 45% of cases are diagnosed while the cancer is still confined to the liver, and these patients have a 37.6% five-year survival rate. When caught at the earliest stages, treatments like surgery or transplant can eliminate the cancer entirely. Even in advanced cases where a cure isn’t possible, newer therapies are extending survival well beyond what was available a decade ago.
What Determines Your Treatment Options
Two factors matter more than anything else in liver cancer treatment: the size and spread of the tumor, and how healthy the remaining liver tissue is. Most people who develop liver cancer already have some degree of liver damage from hepatitis, alcohol use, or fatty liver disease, and that underlying damage limits what treatments the liver can safely tolerate.
Doctors assess liver health using a scoring system that groups patients into three classes. Patients with well-preserved liver function are generally safe candidates for surgery. Those with moderate liver damage can sometimes proceed after medical optimization, but with higher risk. When liver function is severely impaired, major surgery is typically off the table regardless of tumor size, and treatment shifts toward less invasive options or supportive care.
The cancer itself is staged from very early (stage 0) through early, intermediate, and advanced, to end-stage (stage D). Early-stage cancers that haven’t spread beyond the liver offer the most treatment options and the best chance of a cure. Advanced cancers that have spread to blood vessels or other organs are managed with systemic therapies aimed at slowing progression and maintaining quality of life.
Curative Treatments for Early-Stage Disease
When liver cancer is caught early, three approaches can potentially cure it: surgical removal of the tumor, liver transplant, and ablation (destroying the tumor with heat, cold, or other energy).
Surgical Removal
A partial hepatectomy removes the section of the liver containing the cancer. The liver is one of the few organs that can regenerate, so the remaining tissue gradually grows back. This option works best when there’s a single tumor, enough healthy liver to sustain the body after surgery, and no cancer in major blood vessels.
Liver Transplant
Transplant is the most definitive treatment because it removes both the cancer and the diseased liver in one procedure. Not everyone qualifies. The most widely used eligibility standard requires either a single tumor smaller than 5 centimeters or up to three tumors each smaller than 3 centimeters, with no spread beyond the liver and no invasion of major blood vessels. Patients meeting these criteria achieve four-year survival rates around 75%.
Some centers use expanded criteria that allow slightly larger or more numerous tumors while maintaining similar outcomes. One set of criteria permits a single tumor up to 6.5 centimeters or up to three tumors with the largest under 4.5 centimeters, as long as the total tumor diameter stays under 8 centimeters. Five-year survival with these broader criteria is about 75% as well. The main practical barrier is organ availability: wait times for a donor liver can be long, and patients may need bridging treatments to keep the cancer from growing past eligibility thresholds.
Ablation
Ablation destroys tumors without removing them, using heat (radiofrequency or microwave energy), extreme cold, or alcohol injection directly into the tumor. It’s most effective for tumors under 3 centimeters, where initial complete destruction rates exceed 90% and local recurrence runs between 10% and 20%. As tumors grow larger, success drops sharply: recurrence climbs to over 50% for tumors between 2.6 and 4 centimeters, and nearly 70% for those above 4 centimeters. Ablation is a good option for patients who aren’t candidates for surgery due to liver function or tumor location, and it’s sometimes used as a bridge while waiting for a transplant.
Treatments for Intermediate and Advanced Cancer
When surgery, transplant, or ablation aren’t feasible, treatment shifts to approaches that control the cancer rather than eliminate it completely. These therapies can still add months or years of life.
Artery-Based Treatments
Liver tumors get most of their blood supply from the hepatic artery, while healthy liver tissue is fed mainly by the portal vein. This difference allows doctors to target tumors through the artery while largely sparing normal tissue. In chemoembolization, a catheter delivers chemotherapy drugs directly to the tumor, then blocks the feeding blood vessels to cut off oxygen and trap the drugs in place. This combination of chemical and blood-supply attack is the standard first-line treatment for intermediate-stage cancers that can’t be surgically removed.
A newer alternative uses tiny radioactive microspheres instead of chemotherapy drugs. These beads are small enough that they don’t block blood flow the way chemoembolization does, which means fewer side effects like pain and fever after the procedure. The lack of vessel blockage also makes this approach an option for patients whose portal vein is partially blocked by tumor, a situation where chemoembolization is generally too risky.
Immunotherapy and Targeted Therapy
Systemic treatments that circulate through the entire body have transformed outcomes for advanced liver cancer in recent years. The newest first-line option, approved by the FDA in April 2025, combines two immunotherapy drugs that work by releasing the brakes on the immune system. One drug activates immune cells in the lymph nodes while the other enhances their cancer-killing ability within tumors. In a trial of 668 patients with advanced, inoperable liver cancer, this combination achieved a median overall survival of 23.7 months, compared to 20.6 months for patients on standard targeted therapy. More than a third of patients (36%) saw their tumors shrink meaningfully, versus about 13% on the older drugs.
Other first-line options pair an immunotherapy drug with one that blocks the blood vessel growth tumors depend on. These combinations have also shown significant survival improvements over older single-drug approaches. For patients whose cancer progresses on first-line treatment, several second-line targeted drugs are available that block the molecular signals driving tumor growth.
Survival Rates by Stage
Five-year relative survival rates, based on U.S. data from 2015 to 2021, give a broad picture of outcomes:
- Localized (cancer confined to the liver): 37.6%
- Regional (spread to nearby lymph nodes or tissues): 13.2%
- Distant (spread to other organs): 3.5%
These numbers reflect all patients diagnosed during that period, including those with severe underlying liver disease who may not have been candidates for aggressive treatment. Individual outcomes vary significantly based on liver function, tumor characteristics, and which treatments are available. The survival landscape is also shifting: the immunotherapy combinations approved in the last few years weren’t widely used during much of the 2015 to 2021 data window, so current outcomes for advanced disease are likely better than these figures suggest.
Supportive Care for Late-Stage Disease
For patients with end-stage liver cancer, where the liver is severely damaged and disease-directed treatments are no longer effective, median survival is under three months. At this point, the focus shifts entirely to comfort and quality of life. Palliative care teams manage the complex symptoms that come with advanced liver disease: pain, fatigue, fluid buildup in the abdomen, confusion from toxin buildup the liver can no longer filter, nausea, shortness of breath, and significant weight loss.
Palliative care isn’t limited to end-stage disease, though. It can run alongside active treatment at any stage, helping manage side effects from chemoembolization or immunotherapy, supporting difficult decisions about whether to pursue aggressive treatment, and addressing the anxiety and depression that often accompany a cancer diagnosis. Early involvement of palliative care has been shown to improve both symptom control and decision-making throughout the course of illness.
Why Early Detection Changes Everything
The gap between a 37.6% five-year survival for localized disease and 3.5% for distant spread illustrates how dramatically stage at diagnosis shapes outcomes. People at high risk for liver cancer, particularly those with cirrhosis, chronic hepatitis B or C, or advanced fatty liver disease, benefit from regular screening with ultrasound. Tumors found when they’re still small enough for ablation, resection, or transplant offer the clearest path to long-term survival. Even tumors under 1 centimeter may simply be monitored closely rather than treated immediately, because at that size they can be tracked and addressed the moment they show growth.